Abstract:OBJECTIVE:To prepare the SEA-TM and mB7.1-GPI dual-anchored EL-4 cell vaccine and to investigate its antitumor effects.METHODS:mB7.1-GPI-anchored EL-4 cell vaccine, SEA-TM-anchored EL-4 cell vaccine, SEA-TM and mB7.1-GPI dual-anchored EL-4 cell vaccine were prepared. In vitro the biological activities of these vaccines were measured using a lymphocyte proliferation assay and cytokine release assay on splenocytes derived from C57BL/6 mice. The splenocytes were co-cultured with EL-4 or EL-4/mB7.1-GPI or EL-4/SEA-TM or EL-4/SEA-TM + mB7.1-GPI (treated with Mitomycin C). Lymphocyte proliferation was determined with MTT assay, the concentrations of cytokines (IL-2 and IFN-gamma) were measured using a ELISA technique. Forty C57BL/6 mice were inoculated with EL-4 cells, after 3 days the mice were randomly divided into 5 groups with 8 in each and were treated with PBS, EL-4 cell vaccine, EL-4/mB7.1-GPI cell vaccine, EL-4/SEA-TM cell vaccine and EL-4/SEA-TM + mB7.1-GPI cell vaccine respectively, vaccines were injected three time with two-day interval. Animals were observed daily, tumor sizes were measured every third day. Twenty-five days after tumor challenge, 3 mice in each group were sacrificed and splenic lymphocytes were isolated to examine the activity of natural killer cells (NK) and cytolytic T lymphocytes (CTL). The survival of the remaining 5 mice in each group was observed till the 90th day.RESULTS:mB7.1-GPI or/and TM-SEA fusion protein was stably anchored onto the surface of EL-4 tumor cells. EL-4/mB7.1-GPI or EL-4/SEA-TM had a stronger ability to stimulate lymphocyte proliferation and IL-2 and IFN-gamma production than EL-4 (P < 0.05); while EL-4/SEA-TM + mB7.1-GPI showed a further increased ability than EL-4/mB7.1-GPI and EL-4/SEA-TM in stimulating lymphocyte proliferation and cytokine production in vitro (P < 0.05). Volume of tumor was smaller and survival time of mice was longer in EL-4/mB7.1-GPI vaccine group, EL-4/SEA-TM vaccine group and EL-4/SEA-TM + mB7.1-GPI vaccine group, comparing with PBS group and EL-4 cell vaccine group (P < 0.05). Tumor volume was much smaller and survival time of mice was much longer in EL-4/mB7.1-GPI + mB7.1-GPI vaccine group, comparing with EL-4/SEA-TM vaccine group and EL-4/mB7.1-GPI vaccine group (P < 0.05). Lymphocytes derived from the mice treated with EL-4/SEA-TM + mB7.1-GPI showed much higher NK activity and CTL activity than those derived from EL-4/mB7.1-GPI vaccine group and EL-4/SEA-TM vaccine group (P < 0.05), meanwhile the NK activity and CTL activity of EL-4/mB7.1-GPI vaccine group and EL-4/SEA-TM vaccine group was higher than EL-4 vaccine group (P < 0.05).CONCLUSION:mB7.1-GPI or/and SEA-TM fusion protein was stably anchored onto the surface of EL-4 tumor cells. The tumor cell vaccines prepared from these cells exhibited antitumor effect. The mB7.1-GPI and SEA-TM dual-anchored tumor cell vaccine had much stronger antitumor effect than the single-anchored tumor cell vaccine.

Anti-tumor effect induced by recombinant mouse Muc1-MBP fusion protein in vivo

The Anti-Tumor Effect of Recombinant Human MUC1-MBP Fusion Protein

Comparison of anti-tumor effect between human MUC1-MBP and mouse Mucl-MBP fusion protein vaccine

Therapeutic Effect of MIP-1alpha-recruited Dendritic Cells on Preestablished Solid and Metastatic Tumors.

A MUC1-MBP vaccine induces anti-tumor effect in subcutaneous transplantation mouse model of human breast cancer

Preparation of murine lung cancer vaccine modified by macrophagic inflammatory protein 1αand observational study of antitumor activity in vivo

The Effect of Different Immunization Cycles of a Recombinant Mucin1-Maltose-Binding Protein Vaccine on T Cell Responses to B16-MUC1 Melanoma in Mice

[Induction of Specific Cytotoxic T Lymphocytes and Humoral Immune Response by MUC1 DNA Vaccine in Mice].

Expression of human full-length MUC1 inhibits the proliferation and migration of a B16 mouse melanoma cell line.

[The in Vivo Antitumor Activity of Murine Liver Tumor Vaccine Expressing MIP-1alpha].

Preparation of Mb7.1-Gpi and SEA-TM Dual-Anchored Tumor Cell Vaccine and Its Antitumor Effect

MUC1 and maltose‑binding protein recombinant fusion protein combined with Bacillus Calmette‑Guerin induces MUC1‑specific and nonspecific anti‑tumor immunity in mice.

Anti-tumor Effect and Its Mechanism of Co-Administration of Fusion Proteins Hvegf121/βhcg and Mgm-Csf/βhcg

Inhibitory effect of MUC1 gene immunization on H22 hepatocellular carcinoma growth

Antitumor Effect of Adenoviral Vector Prime Protein Boost Immunity Targeting the MUC1 VNTRs

Recombinant MUC1-MBP fusion protein combined with CpG2006 vaccine induces antigen-specific CTL responses through cDC1-mediated cross-priming mainly regulated by type I IFN signaling in mice

Induction of specific T lymphocyte and humoral immune responses by MUC1 DNA vaccine and GM-CSF in mice

Induction of immune response and anti-tumor activities in mice with a DNA vaccine encoding human mucin 1 variable-number tandem repeats.

Immunotherapy of spontaneous mammary carcinoma with fusions of dendritic cells and mucin 1-positive carcinoma cells.

Enhanced inhibitory effect of MUC1 gene vaccine on breast cancer growth by GM-CSF]

The Study on the Lowered Tumorigenicity of Hepatocellular Carcinoma Cells Cotransfected with Chemokine Mmip-1Α and Costimulatory Molecule M4-1Bb L in Vivo